Key result
Sildenafil treatment in patients with persistent pulmonary hypertension after valvular correction was associated with worse clinical outcomes than placebo.
Why the study?
Does sildenafil improve a composite clinical score in stable adult patients with persistent pulmonary hypertension after correction of valvular heart disease?
RCT (n=200)
Double-blind
1:1
Yes
Does sildenafil improve a composite clinical score in stable adult patients with persistent pulmonary hypertension after correction of valvular heart disease?
Answers are grounded in this paper and cite their sources.
Sildenafil worsens clinical outcomes in patients with persistent pulmonary hypertension after valvular correction, reinforcing guidelines against using PAH-approved therapies in PH-LHD.
This editorial refers to ‘Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial’†, by J. Bermejo et al., on page 1255. Pulmonary hypertension (PH) due to left heart disease (PH-LHD) is defined by an increase of the mean pulmonary arterial pressure (PAP) ≥25 mmHg associated with an increase in pulmonary artery wedge pressure (PAWP) >15 mmHg.1 Two different types of PH-LHD have been recognized from pathological, pathophysiological, and haemodynamic points of view.1–3 The first, defined as isolated post-capillary PH (Ipc-PH), is characterized by the simple backward transmission of the increased left atrial pressure through the pulmonary veins and capillaries up to the pulmonary arteries. The second subset, named combined post- and pre-capillary PH (Cpc-PH), comprises a specific distal pulmonary artery disease, which contributes to a further increase of PAP as an addition to the backward transmission (Figure 1).1 , 2 An updated definition of the two PH-LHD haemodynamic forms was proposed in the 2015 European Society of Cardiology/European Respiratory Society (ESC/ERS) PH guidelines:1 Ipc-PH was defined by a diastolic pressure gradient (DPG: pulmonary artery diastolic pressure minus mean pulmonary artery wedge pressure) <7 mmHg and/or pulmonary vascular resistance (PVR) ≤3 Wood units (WU), while Cpc-PH was defined by a DPG ≥7 mmHg and/or PVR >3 WU. Patients with Cpc-PH have a worse prognosis compared with patients with Ipc-PH,4–7 and this has been attributed mainly to the presence of the pre-capillary pathological obstructive component that affects the distal pulmonary arteries. Heart failure with reduced left ventricular ejection fraction (HFrEF), HF with preserved EF (HFpEF), and valvular heart diseases (VHD) are considered the three largest aetiological subgroups of patients with PH-LHD.1 , 7 Pathology: In the pulmonary arterial hypertension box, the pictures show the microscopic and schematic images of distal pulmonary arteries. The first picture from left exhibits severe obstructive medial and intimal proliferation, the second shows a plexiform lesion, and in the third inflammatory cells infiltrate in addition to medial and intimal proliferation. In the pulmonary hypertension due to left heart disease box, the first picture shows interstitial lung oedema and alveolar haemorrhage, while the schematic picture depicts wall thickening of small pulmonary veins and mild intimal proliferation. The second and third pictures show different degrees of medial and intimal obstructive proliferations. Pathophysiology and haemodynamics: Pulmonary arterial hypertension is characterized by a severe increase of mPAP, PVR, and RV systolic pressure. Pulmonary hypertension due to left heart disease is represented by IpcPH (high LA, PV, PAWP, mPAP, and RV systolic pressures) and CpcPH (PVR moderate increase in addition to the IpcPH features). Effective therapies: Treatments recommended for pulmonary arterial hypertension or pulmonary hypertension due to left heart disease. AO: aorta; CpcPH: combined post-capillary pulmonary hypertension; IpcPH: isolated post-capillary pulmonary hypertension; LA: left atrium; LV: left ventricle; mPAP: mean pulmonary artery pressure; PAWP: pulmonary artery wedge pressure; PDE-5: phosphodiesterase type 5; PGI2: prostacyclin 2; PVR: pulmonary vascular resistance; RA: right atrium; RV: right ventricle; sGC: soluble guanylate cyclase; VC: vena cava; Numbers are pressures in mmHg. In this issue of the European Heart Journal, the article of Bermejo et al.8 reports the results of the SIOVAC (Sildenafil for Improving Outcomes after VAlvular Correction) study, which is an investigator-driven, academically sponsored, multicentre, randomized, double-blind, placebo-controlled, parallel clinical trial (RCT) in patients with persistent PH after correction of VHD. Two hundred stable adult patients with mean PAP ≥30 mmHg, who had undergone a successful valve replacement or repair procedure at least 1 year before, were randomized 1:1 to receive sildenafil (40 mg three times daily (t.i.d), n = 104) or placebo (n = 96) for 6 months. The primary endpoint was the composite clinical score combining death, hospital admission for heart failure, change in functional class, and patient global self-assessment. The relevant message of the SIOVAC study is that treatment with sildenafil was associated with worse clinical outcomes than placebo. This conclusion is not surprising if we consider the lack of favourable clinical outcomes reported by RCTs with sildenafil either in patients with LHD or PH-LHD.2 The ESC/ERS PH guidelines1 clearly state that ‘“the use of PAH-approved therapies is not recommend in patients with PH-LHD”’, with a grade of recommendation I and a level of evidence C. As reported also in the paper of Bermejo et al., this has not prevented a large amount of off-label use of sildenafil and of other PAH-approved therapies in patients with PH-LHD. This improper attitude, based mainly on the preliminary results of small single-centre studies, has no pathological, pathophysiological, or haemodynamic rationale or multicentre RCT support (Figure 1 and Table 1). Randomized controlled trials performed in patients with heart failure due to left heart disease using drugs approved for pulmonary arterial hypertension and reporting data on mortality HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; mPAP, mean pulmonary arterial pressure; N/A, not assessed; PAP, pulmonary arterial pressure; sPAP, systolic pulmonary arterial pressure; VHD, valvular heart disease. Numbers are in mmHg. Randomized controlled trials performed in patients with heart failure due to left heart disease using drugs approved for pulmonary arterial hypertension and reporting data on mortality HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; mPAP, mean pulmonary arterial pressure; N/A, not assessed; PAP, pulmonary arterial pressure; sPAP, systolic pulmonary arterial pressure; VHD, valvular heart disease. Numbers are in mmHg. The pathological changes observed in the distal pulmonary arteries observed in PAH patients are largely different from those observed in PH-LHD patients. In the former, pathological changes predominantly affect the distal pulmonary arteries (diameter < 500 µm) with medial hypertrophy, intimal proliferative and fibrotic changes, and adventitial thickening, with mild to moderate perivascular inflammatory infiltrates and lymphoid neogenesis (Figure 1). In addition, complex lesions such as dilated and plexiform lesions are considered as a hallmark of PAH histology, and correspond to an exuberant proliferation of endothelial cells within a dilated, thin-walled arterial lumen (Figure 1). Pulmonary veins are classically unaffected.9 Pulmonary vascular disease in patients with PH-LHD (Figure 1) is characterized by enlarged and thickened pulmonary veins, pulmonary capillary dilatation, interstitial oedema, alveolar haemorrhage, lymphatic vessels, and lymph node enlargement.3 In addition, the pre-capillary circulation may also be involved at the level of distal pulmonary arteries, which may be affected by different degrees of obstructive remodelling such as medial hypertrophy, and intimal fibrosis and proliferation. The presence of this pre-capillary component, which is considered exclusive of the Cpc-PH, form has been described in the past,3 and confirmed in more recent analyses from biopsies, autopsies, and lungs resections.2 , 4 The pathobiological and pathological changes of the distal pulmonary arteries of patients with PAH are the targets for the approved medications,10 and the relevant diversity of the changes observed in the distal vasculature of PH-LHD subjects does not support a sound rationale for the use of PAH-approved drugs in these patients. The pathophysiology and haemodynamics of PAH patients are characterized by pre-capillary pulmonary hypertension with normal values for left atrial and left ventricular pressures (Figure 1). The predominant feature is a severe increase of PVR and of right ventricular afterload. Conversely, in patients with PH-LHD, the initiating mechanism is an increase of left atrial pressure that is transmitted backward to the pulmonary veins, the pulmonary capillaries, and the pulmonary arteries (Figure 1). The pre-capillary component characterized by mild to moderate obstructive lesions in the distal pulmonary arteries contributes to the increase of PAP in patients with Cpc-PH. Only in these patients are mild to moderate increases of PVR7 and more prominent increases of right ventricular afterload observed. However, we cannot consider Cpc-PH patients in the same disease spectrum of PAH, as suggested by some authors,11 due to the striking differences in the originating mechanism (increase of left atrial pressure) and in the pathological changes, and the coexistence of a LHD. The only unifying feature of Cpc-PH and PAH is the increase of PVR, which is clearly insufficient to include them in a similar pathophysiological condition, which theoretically should comprise also all other forms of PH with elevated PVR.1 The ESC/ERS PH guidelines1 suggest an evidence-based treatment algorithm for PAH patients, including drugs interfering with the endothelin (endothelin receptor antagonists, ERAs), nitric oxide (phosphodiesterase type-5 inhibitors, PDE-5is, and soluble guanylate cyclase stimulators, sGCs) and prostacyclin (prostacyclin analogues, PAs, and prostacyclin receptor agonists, PRAs) pathways. These molecules have been tested in 41 multicentre RCTs and approved by regulatory agencies based on favourable results on symptoms, exercise capacity, haemodynamics, and prognosis. The same drugs have been tested in single and multicentre RCTs in patients with LHD due to HFrEF, HFpEF, and VHD with or without PH. The majority of the RCTs did not show favourable effects in LHD patients (except a few single-centre RCTs), and some raised concerns about safety due to fluid retention. However, the SIOVAC study is the first to clearly report a relevant increase of unfavourable clinical events in patients with PH-LHD treated with PAH-approved drugs such as sildenafil. In Table 1, we report the data of 12 RCTs (11 multicentre) with the use of ERA, PA, PDE5i, and sGC stimulators in LHD patients in which safety data have been described in detail, including mortality. The studies involved either HFrEF, HFpEF, or VHD, and at least six RCTs partially or exclusively included patients with PH. It is also conceivable that PH-LHD patients were also in part included in the six RCTs in which PH data were not reported. Interestingly, the mortality was higher in the active drug-treated groups in 9 out of the 12 RCTs, and in 5 out of the 6 RCTs partially or exclusively including PH-LHD patients. Despite the heterogeneity of these RCTs, we believe that these data reinforce the safety concerns raised by the paper by Bermejo et al. on the use of PAH-approved drugs in PH-LHD patients. Therefore, the level of evidence for the ESC/ERS PH guidelines recommendation not to use PAH-approved drugs in PH-LHD patients should be raised from C to B. The reasons for the unfavorable effects of PAH-approved drugs in PH-LHD patients are unclear and may include the reduction of blood pressure and the consequent fluid retention effect, or the increase of PAWP due to the pre-capillary vasodilatation exerted by these compounds, as shown after the acute administration of nitric oxide.12 In the study of Bermejo et al., the acute administration of sildenafil lowered pulmonary pressures and increased cardiac output, while long-term administration induced both left and right ventricle dilatation as compared with placebo, suggesting a possible negative inotropic effect of sildenafil in the setting of PH-LHD. Interestingly, the use of left ventricular assist devices (LVADs) in HFrEF patients with CpcPH (not reversible with pharmacological challenge) is able to reduce the PAWP, PAP, and PVR as soon as after 3 days, and to completely normalize these parameters after 6 weeks.13 This phenomenon may be explained by the reverse-remodeling of the distal pulmonary arteries’ fixed obstructive lesions in response to the prolonged normalization of the PAWP induced by LVADs. In other words, targeting the “primum movens” for the development of both IpcPH and CpcPH, which is the increase of left atrial pressure, seems to be the appropriate strategy in this patient population. In contrast, directly targeting the pulmonary vascular disease is not effective and can be harmful, as shown in the study by Bermejo et al. While the reduction and possibly the normalization of the PAWP may be feasible in subsets of patients with HFrEF or VHD with available treatments, this is more difficult in HFpEF patients due to the lack of effective drug therapies for this condition.14 , 15 This work was supported by the Department of Investigational, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy and the National Institute of Biostructures and Biosystems, Rome, Italy. Conflict of interest: none declared
No takes yet. Share an insight, caveat, or question.
Galiè et al. (2017) conducted an RCT in Persistent pulmonary hypertension after correction of valvular heart disease (n=200). Sildenafil vs. Placebo was evaluated on Composite clinical score combining death, hospital admission for heart failure, change in functional class, and patient global self-assessment. Sildenafil treatment in patients with persistent pulmonary hypertension after valvular correction was associated with worse clinical outcomes than placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: